Peroxisome proliferator-activated receptor gamma (PPARγ), a multiple functional transcription factor, has been reported to have anti-tumor effects through inhibition of cells proliferation. However, its effects on cardiac myxoma (CM) cells and the underlying signaling mechanism is unclear. In the present study, we demonstrated that the level of PPARγ is inversely correlated with that of myocyte enhancer factor 2D (MEF2D), a biomarker of CM. We found that activation of PPARγ inhibit MEF2D expression via upregulation of miR-122, which can target the 3'-UTR of MEF2D and inhibit MEF2D expression, by directly binding to the PPRE in the miR-122 promoter region. Functional experiments further showed that miR-122-dependent downregulation of MEF2D by PPARγ suppress the proliferation of CM cells. These results suggest that PPARγ may exert its antiproliferative effects by negatively regulating the MEF2D in CM cells, which through upregulation of miR-122, and PPARγ/miR-122/MEF2D signaling pathway may be a novel target for treatment of CM.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbrc.2016.04.112 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Percutaneous Excision of Left Atrial Myxoma Using Transcatheter Electrosurgery.
JACC Case Rep
January 2025
Cardiology Department, Centre hospitalier de l'université de Montréal, Montréal, QC, Canada.
Left atrial myxoma is the most prevalent primary cardiac tumor, known for its high risk of systemic embolization. Although surgical excision remains the standard treatment, options are limited for high-risk patients. This case report introduces a novel approach using transcatheter electrosurgery to address a left atrial myxoma via a transseptal approach in a patient ineligible for conventional surgery due to the heightened risk of intracranial hemorrhage associated with cerebral amyloid angiopathy.
View Article and Find Full Text PDFLeft Atrial Papillary Fibroelastoma Mimicking Myxoma.
JACC Case Rep
January 2025
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Papillary fibroelastomas (PFEs) followed by cardiac myxomas (CM) are the 2 most common primary benign cardiac tumors. Although typically asymptomatic, they can manifest with nonspecific symptoms such as dyspnea and dizziness or more acute manifestations such as embolic events. We describe an unusual location of a PFE typically seen with a CM.
View Article and Find Full Text PDFRegrowth Rate of a Cardiac Myxoma After Percutaneous Aspiration.
JACC Case Rep
January 2025
Department of Cardiology, Lankenau Medical Center, Wynnewood, Pennsylvania, USA.
Cardiac myxomas are typically treated surgically; however, the operative mortality and recurrence rates are not negligible. In the current report we describe a case of repeat percutaneous aspiration of a right atrial myxoma. The report supports feasibility of the procedure, provides the asymptomatic timeframe after debulking, and the regrowth rate.
View Article and Find Full Text PDFNovel Use of a Catheter-Based Device Retrieval System for Percutaneous Treatment of Recurrent Atrial Myxoma.
JACC Case Rep
January 2025
Department of Cardiology, Kaiser Permanente Downey Medical Center, Downey, California, USA.
Surgical resection is standard of care for the treatment of atrial myxoma. However, the optimal management strategy for recurrent cardiac tumors is less clear. Here we report the novel use of a catheter-based device retrieval system for the removal of a recurrent cardiac myxoma.
View Article and Find Full Text PDFTranscatheter Cardiac Tumor Excision: Growing the Toolbox.
JACC Case Rep
January 2025
St Francis Hospital and Heart Center, Roslyn, New York, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!